Anecortave Acetate Risk-Reduction Trial (AART)

• Status: Terminated
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Anecortave; Hydrocortisone

Criteria

Inclusion Criteria:

• Dry AMD study eye, Wet AMD non-study eye.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Age

• Other protocol-defined exclusion criteria may apply.